Biological insight in new drug combinations

BRIM8: Vemurafenib in high risk melanoma patients

Durvalumab in novel combinations for head and neck cancer

COMBI-AD: Dabrafenib plus trametinib in advanced melanoma

Expert commentary on melanoma immunotherapy latest

Vemurafenib for high risk melanoma patients

Dabrafenib plus trametinib for stage III mutant melanoma

Nivolumab vs ipilimumab for high risk melanoma patients

Checkmate 238: Adjuvant checkpoint therapy after melanoma resection

The role of tumour marker testing in early diagnosis

The METRIC trial of trametinib, five years on

Patient perceptions of chemotherapy side effects differ over time and treatment